BioSight
Companies
PureTech Health plc logo

PRTC

NASDAQBOSTON, MA
PureTech Health plc

PureTech Health plc operates a portfolio of wholly-owned drug programs and founded entities developing therapeutic candidates across multiple indications, with lead programs including deupirfenidone (LYT-100) and LYT-200. The company is in the preclinical and clinical development stage, working toward regulatory approval for its therapeutic candidates. PureTech also maintains ownership stakes in founded entities that are separately developing their own therapeutic candidates.

Price history not yet available for PRTC.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar